Healthcare provider profile · identity verified

Steven H Reed

Internal Medicine · BROOKLYN CENTER, MN · NPI 1336125772

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	674	195
Rosuvastatin Calcium	Rosuvastatin Calcium	366	99
Amlodipine Besylate	Amlodipine Besylate	355	105
Lisinopril	Lisinopril	336	81
Losartan Potassium	Losartan Potassium	302	95
Metoprolol Succinate	Metoprolol Succinate	276	77
Levothyroxine Sodium	Levothyroxine Sodium	270	66
Omeprazole	Omeprazole	242	70
Tamsulosin Hcl	Tamsulosin Hcl	201	64
Metformin Hcl	Metformin Hcl	184	44
Metformin Hcl Er	Metformin Hcl	163	55
Allopurinol	Allopurinol	142	37
Atenolol	Atenolol	134	41
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	129	40
Warfarin Sodium	Warfarin Sodium	128	29
Furosemide	Furosemide	126	40
Gabapentin	Gabapentin	114	48
Glipizide Er	Glipizide	114	32
Simvastatin	Simvastatin	109	30
Albuterol Sulfate Hfa	Albuterol Sulfate	96	37
Ozempic	Semaglutide	89	15
Potassium Chloride	Potassium Chloride	85	29
Hydrochlorothiazide	Hydrochlorothiazide	81	29
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	81	26
Eliquis	Apixaban	75	25
Fluticasone Propionate	Fluticasone Propionate	74	29
Fluoxetine Hcl	Fluoxetine Hcl	71	16
Finasteride	Finasteride	69	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	69	23
Trazodone Hcl	Trazodone Hcl	69	19
Jardiance	Empagliflozin	66	20
Pravastatin Sodium	Pravastatin Sodium	66	17
Clopidogrel	Clopidogrel Bisulfate	64	20
Spironolactone	Spironolactone	64	18
Carvedilol	Carvedilol	59	16
Famotidine	Famotidine	59	26
Tramadol Hcl	Tramadol Hcl	57	12
Xarelto	Rivaroxaban	55	17
Pantoprazole Sodium	Pantoprazole Sodium	52	16
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	47	14
Doxazosin Mesylate	Doxazosin Mesylate	47	14
Duloxetine Hcl	Duloxetine Hcl	46	16
Metoprolol Tartrate	Metoprolol Tartrate	46	11
Torsemide	Torsemide	43	18
Triamcinolone Acetonide	Triamcinolone Acetonide	43	25
Chlorthalidone	Chlorthalidone	42	11
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	20
Bupropion Xl	Bupropion Hcl	40	11
Trulicity	Dulaglutide	40	12
Mirtazapine	Mirtazapine	37	suppressed
Citalopram Hbr	Citalopram Hydrobromide	36	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	36	12
Anoro Ellipta	Umeclidinium Brm/Vilanterol Tr	35	suppressed
Levetiracetam	Levetiracetam	34	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	33	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Alprazolam	Alprazolam	32	suppressed
Spironolactone-Hctz	Spironolact/Hydrochlorothiazid	32	suppressed
Sertraline Hcl	Sertraline Hcl	31	15
Rybelsus	Semaglutide	27	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	27	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	26	suppressed
Lorazepam	Lorazepam	26	suppressed
Glimepiride	Glimepiride	25	suppressed
Montelukast Sodium	Montelukast Sodium	25	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	25	11
Humalog Kwikpen U-100	Insulin Lispro	24	suppressed
Mounjaro	Tirzepatide	24	suppressed
Soliqua 100-33	Insulin Glargine/Lixisenatide	24	suppressed
Alendronate Sodium	Alendronate Sodium	23	suppressed
Ezetimibe	Ezetimibe	23	suppressed
Hydralazine Hcl	Hydralazine Hcl	23	suppressed
Atenolol-Chlorthalidone	Atenolol/Chlorthalidone	22	suppressed
Estradiol	Estradiol	22	suppressed
Lovastatin	Lovastatin	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	21	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	21	suppressed
Prednisone	Prednisone	21	14
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	21	suppressed
Valacyclovir	Valacyclovir Hcl	21	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Glipizide	Glipizide	16	suppressed
Hydromorphone Hcl	Hydromorphone Hcl	16	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	16	suppressed
Oxycodone Hcl	Oxycodone Hcl	16	suppressed
Solifenacin Succinate	Solifenacin Succinate	16	suppressed
Betamethasone Diprop Augmented	Betamethasone/Propylene Glyc	15	suppressed
Cephalexin	Cephalexin	15	suppressed
Digoxin	Digoxin	15	suppressed
Paroxetine Hcl	Paroxetine Hcl	15	suppressed
Bumetanide	Bumetanide	14	suppressed
Ondansetron Odt	Ondansetron	14	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	14	12
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	12
Azithromycin	Azithromycin	13	suppressed
Baclofen	Baclofen	13	suppressed
Darifenacin Er	Darifenacin Hydrobromide	13	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Ketoconazole	Ketoconazole	13	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Nystatin	Nystatin	12	suppressed
Potassium Citrate Er	Potassium Citrate	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	11	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	11	suppressed
Ibandronate Sodium	Ibandronate Sodium	11	suppressed
Loperamide	Loperamide Hcl	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed
Ventolin Hfa	Albuterol Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error